Invention Publication
EP2938344A1 PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
有权
哌嗪[1,2,4]三唑[1,5-C]喹唑啉-5-氨基 - 维生素M11A-ANTAGONISTISCHEN EIGENSCHAFTEN
- Patent Title: PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
- Patent Title (中): 哌嗪[1,2,4]三唑[1,5-C]喹唑啉-5-氨基 - 维生素M11A-ANTAGONISTISCHEN EIGENSCHAFTEN
-
Application No.: EP13867977.4Application Date: 2013-12-20
-
Publication No.: EP2938344A1Publication Date: 2015-11-04
- Inventor: ALI, Amjad , LO, Michael Man-Chu , LIM, Yeon-Hee , STAMFORD, Andrew , KUANG, Rongze , TEMPEST, Paul , YU, Younong , BERLIN, Michael , TING, Pauline , ZHOU, Gang , YU, Tao , BOYCE, Christopher , KELLY, Joseph Michael , TAGAT, Jayaram, R. , ZHENG, Junying , HUANG, Xianhai , ZHOU, Wei , KIM, Jae-Hun , ZORN, Nicolas , XIAO, Dong , GALLO, Gioconda, V. , WON, Walter , WU, Heping , ANAND, Rajan , DENG, Qiaolin
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: 126 East Lincoln Avenue Rahway, NJ 07065-0907 US
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: 126 East Lincoln Avenue Rahway, NJ 07065-0907 US
- Agency: Buchan, Gavin MacNicol
- Priority: PCT/CN2012/087851 20121228
- International Announcement: WO2014105664 20140703
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; A61K31/519
Abstract:
Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
Information query
IPC分类:
